US › Healthcare

Alumis Inc (ALMS)

US · Healthcare · Biotechnology

$27.12+3.83%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.7M
Revenue YoY
-90.0%
Net profit
$-93.1M
Profit YoY
+6.0%
EPS
$-0.74
EPS estimate
$-0.77
Net margin
-5,344.8%

EPS came in at -0.74 against a street estimate of -0.77 — a beat of 3.9%.

Key statistics

Market cap
$3.60B
Forward P/E
0.0
P/B
6.35
Book value
$4.46
EPS (TTM)
$-1.78
52-week high
$31.35
52-week low
$3.76
50-day MA
$24.97
200-day MA
$19.97
Beta
-0.71

Analyst view

Analysts rate Alumis Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $40.11.

Shareholding

Insiders
0.62%
Institutions
100.20%

Largest institutional holders

FundStake
BlackRock Inc5.62%
Deep Track Capital, LP5.31%
Samsara BioCapital, LLC4.98%
Foresite Capital Management V, LLC4.63%
venBio Partners LLC3.55%
Foresite Capital Management VI LLC3.33%
Vanguard Capital Management, LLC3.16%
Cormorant Asset Management, LLC3.10%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-07-02
Company announcement · Q2 20262026-06-29
Proxy statement · Q2 20262026-05-18
Quarterly report · Q1 20262026-05-14
Results announced · Q2 20262026-05-14
Company announcement · Q1 20262026-03-30
Annual report FY20252026-03-19
Quarterly report · Q3 20252025-11-13

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alumis Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.